Co-Founder and CEO at Snipr Biome Christian Grøndahl is very excited about the fact that the US Food and Drug Administration (FDA) recently awarded its special fast-track designation to the biotech company’s candidate, SNIPR001.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Acquisitions to help Coloplast attain growth goal
Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions.
FDA approves Ferring microbiotica-based treatment
Ferring Pharmaceuticals has received US approval for its stomach infection treatment.
QA Specialist 
Principal Systems Engineer 
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
External Manufacturing Leads 
Research Scientist (maternity cover) 
Laboratory assistants for an exciting QC department 
Medical Manager Denmark & Norway 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Chief consultant for Dansk Erhvervs Health and life science 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
New Product Introduction Manager Nordics 
Supply Chain Manager